GgoogleGB first seen 4 h ago, last 9 min ago, peak #3
Eli Lilly's retatrutide cuts weight by 21% in diabetes trial
Original: retatrutide
Eli Lilly's experimental drug retatrutide helped people with type 2 diabetes lose around 21% of their body weight in a clinical trial, according to Reuters. The injectable, which targets multiple hormones, is being closely watched as a potential next-generation obesity treatment following the success of tirzepatide and semaglutide.
Why now: New trial results for Eli Lilly's obesity and diabetes drug retatrutide were just reported, drawing wide interest as the race for next-generation weight-loss treatments heats up.
Rank over time, top of the chart is #1. 19 snapshots from 4 h ago to 9 min ago.
Evidence
- People with Type 2 diabetes lost up to 60 pounds on Lilly’s latest weight loss drug · NBC News
- Lilly's experimental drug cuts weight by 21% in diabetes trial · Reuters
- Most powerful obesity drug yet: People lost up to 25% of weight in trial · Ars Technica
Elsewhere
API: https://socialmediatrends-api.osmike.com/v1/trends/416929